128 related articles for article (PubMed ID: 18314629)
21. Prognostic significance of neuron-associated protein expression in non-muscle-invasive urothelial bladder cancer.
Mhawech-Fauceglia P; Ali L; Cheney RT; Groth J; Herrmann FR
J Clin Pathol; 2009 Aug; 62(8):710-4. PubMed ID: 19638542
[TBL] [Abstract][Full Text] [Related]
22. Tissue microarray based analysis of prognostic markers in invasive bladder cancer: much effort to no avail?
Liedberg F; Anderson H; Chebil G; Gudjonsson S; Höglund M; Lindgren D; Lundberg LM; Lövgren K; Fernö M; Månsson W
Urol Oncol; 2008; 26(1):17-24. PubMed ID: 18190825
[TBL] [Abstract][Full Text] [Related]
23. Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?
Soukup V; Babjuk M; Dusková J; Pesl M; Szakáczová M; Zámecník L; Dvorácek J
Urol Int; 2008; 80(4):413-8. PubMed ID: 18587253
[TBL] [Abstract][Full Text] [Related]
24. Recent developments in molecular profiling of bladder cancer.
Ørntoft TF; Zieger K; Dyrskjøt L
Curr Opin Urol; 2006 Sep; 16(5):377-81. PubMed ID: 16905986
[TBL] [Abstract][Full Text] [Related]
25. Novel use of a combined artificial intelligence approach to identify patients with noninvasive urothelial cell carcinoma of the urinary bladder who are at greatest risk for progression to muscle-invasive disease: a step forward.
DeGraff DJ
Eur Urol; 2010 Mar; 57(3):407-8; discussion 408-9. PubMed ID: 19945780
[No Abstract] [Full Text] [Related]
26. Molecular changes in superficial bladder cancer.
Vrabie CD; Petrescu A; Waller M
Rom J Morphol Embryol; 2007; 48(2):131-8. PubMed ID: 17641799
[TBL] [Abstract][Full Text] [Related]
27. Secreted CXCL1 is a potential mediator and marker of the tumor invasion of bladder cancer.
Kawanishi H; Matsui Y; Ito M; Watanabe J; Takahashi T; Nishizawa K; Nishiyama H; Kamoto T; Mikami Y; Tanaka Y; Jung G; Akiyama H; Nobumasa H; Guilford P; Reeve A; Okuno Y; Tsujimoto G; Nakamura E; Ogawa O
Clin Cancer Res; 2008 May; 14(9):2579-87. PubMed ID: 18451219
[TBL] [Abstract][Full Text] [Related]
28. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor.
Kim EJ; Kim YJ; Jeong P; Ha YS; Bae SC; Kim WJ
J Urol; 2008 Sep; 180(3):1141-5. PubMed ID: 18639281
[TBL] [Abstract][Full Text] [Related]
29. [Management of Ta, T1, and in situ bladder carcinoma: what is new?].
Irani J
Prog Urol; 2008 May; 18 Suppl 5():S94-8. PubMed ID: 18585634
[TBL] [Abstract][Full Text] [Related]
30. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens.
Kunju LP; You L; Zhang Y; Daignault S; Montie JE; Lee CT
J Urol; 2008 Nov; 180(5):1928-32; discussion 1932. PubMed ID: 18801529
[TBL] [Abstract][Full Text] [Related]
31. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?
Knowles MA
Carcinogenesis; 2006 Mar; 27(3):361-73. PubMed ID: 16352616
[TBL] [Abstract][Full Text] [Related]
32. Predicting recurrence and progression in non-muscle-invasive bladder cancer using European organization of research and treatment of cancer risk tables.
Ather MH; Zaidi M
Urol J; 2009; 6(3):189-93. PubMed ID: 19711273
[TBL] [Abstract][Full Text] [Related]
33. Decreased expression of galectin-3 predicts tumour recurrence in pTa bladder cancer.
Kramer MW; Kuczyk MA; Hennenlotter J; Serth J; Schilling D; Stenzl A; Merseburger AS
Oncol Rep; 2008 Dec; 20(6):1403-8. PubMed ID: 19020721
[TBL] [Abstract][Full Text] [Related]
34. A chemosensitivity test to individualize intravesical treatment for non-muscle-invasive bladder cancer.
Gazzaniga P; Gradilone A; de Berardinis E; Sciarra A; Cristini C; Naso G; di Silverio F; Frati L; Aglianò AM
BJU Int; 2009 Jul; 104(2):184-8. PubMed ID: 19154503
[TBL] [Abstract][Full Text] [Related]
35. Neurofuzzy modeling to determine recurrence risk following radical cystectomy for nonmetastatic urothelial carcinoma of the bladder.
Catto JW; Abbod MF; Linkens DA; Larré S; Rosario DJ; Hamdy FC
Clin Cancer Res; 2009 May; 15(9):3150-5. PubMed ID: 19336522
[TBL] [Abstract][Full Text] [Related]
36. Association of TSC1/hamartin, 14-3-3sigma, and p27 expression with tumor outcomes in patients with pTa/pT1 urothelial bladder carcinoma.
Mhawech-Fauceglia P; Alvarez V; Fischer G; Beck A; Herrmann FR
Am J Clin Pathol; 2008 Jun; 129(6):918-23. PubMed ID: 18480009
[TBL] [Abstract][Full Text] [Related]
37. Comparative promoter methylation analysis of p53 target genes in urogenital cancers.
Christoph F; Hinz S; Weikert S; Kempkensteffen C; Schostak M; Miller K; Schrader M
Urol Int; 2008; 80(4):398-404. PubMed ID: 18587251
[TBL] [Abstract][Full Text] [Related]
38. Grade-dependent effects on cell cycle progression and apoptosis in response to doxorubicin in human bladder cancer cell lines.
Stravopodis DJ; Karkoulis PK; Konstantakou EG; Melachroinou S; Lampidonis AD; Anastasiou D; Kachrilas S; Messini-Nikolaki N; Papassideri IS; Aravantinos G; Margaritis LH; Voutsinas GE
Int J Oncol; 2009 Jan; 34(1):137-60. PubMed ID: 19082486
[TBL] [Abstract][Full Text] [Related]
39. Safety of active surveillance program for recurrent nonmuscle-invasive bladder carcinoma.
Hernández V; Alvarez M; de la Peña E; Amaruch N; Martín MD; de la Morena JM; Gómez V; Llorente C
Urology; 2009 Jun; 73(6):1306-10. PubMed ID: 19375783
[TBL] [Abstract][Full Text] [Related]
40. Bcl-XL and Bcl-2 expression in bilharzial squamous cell carcinoma of the urinary bladder: which protein is prognostic?
Hameed DA; Abdel Raheem AM; Mosad E; Hammouda HM; Kamel NA; Abdel Aziz MA
Urology; 2008 Aug; 72(2):374-8. PubMed ID: 18342927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
